Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expression Profiles And Prognostic Implications Of Clinically Actionable Tumor-Associated Antigens Across Diverse Clinicopathological Subtypes of Prostate Cancer: a Bidirectional Cohort Study

NCT07597369 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT07597369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07597369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expression Profiles And Prognostic Implications Of Clinically Actionable Tumor-Associated Antigens Across Diverse Clinicopathological Subtypes of Prostate Cancer: a Bidirectional Cohort Study
Lead sponsor
Peking University First Hospital
Phase
Observational
Overall status
Active, not recruiting
Start date
January 1, 2026
Completion date
January 1, 2029
Enrollment
1,600 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate cancer, metastatic prostate cancer (mcrpc), prostate cancer